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Sex Med 2Introduction: Serotonin reuptake inhibitors (SRIs) are widely used for the treatment of psychiatric disorders,
including obsessive-compulsive disorder (OCD). SRIs commonly cause delayed orgasm, themechanism of which is
poorly understood. Oxytocin is involved in sexual function and is interconnected with serotonin within the brain.
SRIs are reported to affect the oxytocin system, but possible relations between SRI-induced changes of sexual
function and oxytocin are unexplored in humans. In a randomized, double-blinded, placebo-controlled trial of
OCD, the anti-obsessive efﬁcacy and adverse events of SRIs and oxytocin measurements were studied.
Aims: To identify possible correlates between oxytocin levels and sexual function; ﬁnd out whether sexual side
effects correlate with levels of oxytocin and/or paroxetine and clomipramine; and test whether changes in sexual
functioning are related to an anti-obsessive response.
Methods: Reported sexual function and oxytocin plasma levels at rest were studied in 31 adults (15 men and 16
women) with OCD who participated in a randomized, double-blinded trial comparing the SRIs clomipramine
and paroxetine with placebo. Sexual adverse effects were quantiﬁed by a clinician-administered semistructured
interview. Anti-obsessive response was based on the Yale-Brown Obsessive-Compulsive Scale.
Main Outcome Measures: Ratings on the Sexual Symptom Checklist, plasma oxytocin, serum paroxetine and
clomipramine levels, and Yale-Brown Obsessive-Compulsive Scale scores.
Results: Baseline oxytocin levels were positively correlated with baseline OCD severity, but not with sexual
functioning. Impaired orgasm at week 6 was reported by 73% of SRI-treated and 20% of placebo-treated patients
(P¼ .03). Impaired orgasm was related to higher oxytocin levels after 4 weeks of SRI treatment (P< .01) but not to
SRI concentrations. In men, an association between impaired orgasm and anti-obsessive treatment response was
found (P ¼ .028).
Conclusion: This pilot study suggests that some collateral effects of SRIs, particularly delayed orgasm, might be
inﬂuenced by changes within the oxytocinergic system and are related to anti-obsessive mechanisms. Early-onset
delayed orgasm in SRI-treated patients could serve as a predictor for OCD treatment response.
Sex Med 2016;4:e145ee155. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Antidepressant-Induced Sexual Dysfunction,
Serotonergic, and Oxytocinergic Mechanisms
In clinical practice, treatment with potent serotonin reuptake
inhibitors (SRIs; eg, selective serotonin reuptake inhibitors
[SSRIs], serotonin-noradrenaline reuptake inhibitors, and the
tricyclic antidepressant clomipramine) is commonly associatede145
e146 Humble and Bejerotwith sexual side effects. The frequency of these side effects has
been debated, because in major depression (the most common
indication for SRIs) sexual dysfunction constitutes a typical
symptom of the disorder. However, in patients without sexual
dysfunction at baseline, SRIs often induce decreased libido and
delayed orgasm and/or ejaculation.1,2 The speciﬁcity of seroto-
nergic mechanisms is evident, because serotonergic antidepres-
sants cause a much higher rate of sexual dysfunction than
noradrenergic drugs, especially concerning orgasmic function.2,3
Thus, SRIs seem to affect most speciﬁcally orgasmic function,
which is further supported by the fact that SSRIs (eg, paroxetine
and dapoxetine) currently constitute ﬁrst-line pharmacologic
treatment of premature ejaculation.4 Despite the usefulness of
this side effect of SSRIs in andrology, in psychiatric practice, it is
mainly viewed as an undesired adverse effect. In any case, further
knowledge of the neurochemical mechanisms is warranted.
Concerning the role of various serotonin (5-hydroxy-tryptamine
[5-HT]) receptors, agonists on 5-HT1A receptors have been
found to facilitate, whereas 5-HT1B agonists have been found to
inhibit or delay, ejaculatory functions in rats.5e7 Not only direct
effects of changed serotonergic transmission, but also indirect
effects of serotonin, such as inhibited dopamine release,8 or
increased prolactin levels9 have been mechanistically implicated.
However, serotonin has increasingly been shown to interact with
the hypothalamic-neurohypophyseal hormone oxytocin, which
clearly is involved in sexual functions, although its role in human
sexuality is insufﬁciently deﬁned.10e12 Serotonin increases the
hypothalamic mRNA expression of oxytocin by stimulating
5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptors
13 and in-
creases oxytocin release by 5-HT1A, 5-HT2C and 5-HT4
receptors.14 Plasma oxytocin increases rapidly after SSRI
administration in rats,15 and the therapeutic effect of SSRIs
might be mediated by oxytocin.15,16 Conversely, oxytocin might
modulate the release of serotonin in mice17 and humans.18 SSRI
treatment leads to downregulation of 5-HT1A receptors after
approximately 1 week,19,20 thereby potentially decreasing
oxytocin activity. Because 5-HT1A receptor activation releases
oxytocin and facilitates ejaculation in rats, de Jong et al21 sug-
gested that SSRI-induced delayed orgasm might be related to
downregulation of 5-HT1A receptors and decreased oxytocin
activity.
However, it should be noted that, with few exceptions,10,11,18
these studies were performed in rodents, and to our knowledge,
no human studies relating oxytocin and serotonin measurements
with sexual function are available. Two single cases of male sexual
dysfunction (not caused by SSRIs) were reportedly improved by
intranasal oxytocin22,23; however, when intranasal oxytocin was
administered to 10 male volunteers, a moderate but signiﬁcant
delay of ejaculation was recorded.11
Serotonin and Oxytocin in Obsessive-Compulsive
Disorder
Obsessive-compulsive disorder (OCD) is a psychiatric disorder
that frequently has a long-term course and does not includesexual dysfunction among its typical symptoms. Some speciﬁc
symptoms (eg, obsessions related to contamination, religion, or
sexuality) can interfere with sexual function,24 but sexual
obsessions have been found in only 13% of adult patients with
OCD.25 In a direct comparison of sexual dysfunction, patients
with OCD were more similar to healthy controls than to patients
with a major depressive disorder.26 Because of early ﬁndings that
the potent SRI clomipramine has a speciﬁc anti-obsessive
effect,27 pathophysiologic research on OCD has focused on
serotonin.28,29 Currently, SRIs are the main pharmacologic anti-
obsessive treatment, but a clinical problem is the long delay of
therapeutic response.30 Interestingly, Ackerman et al31,32 found
relations between sexual side effects of SRIs and the anti-
obsessive clinical response, with early-onset sexual dysfunction
being the side effect most consistently predicting a response to
the SSRI ﬂuoxetine.
Oxytocin also has been implicated in the pathophysiology of
OCD.33,34 In a previous study, we investigated how SRIs change
oxytocin levels in patients with OCD.35 We found higher plasma
oxytocin levels after 4 weeks of treatment in SRI responders
compared with non-responders.
Accordingly, drug-induced sexual effects are common in SRI-
treated patients, but the mechanisms of these effects are insuf-
ﬁciently studied. A putative role of oxytocin is unsubstantiated in
humans, because, to our knowledge, oxytocinergic measurements
in relation to sexual functions in SRI-treated humans have not
been reported.AIMS
While investigating SRI treatment of OCD, we had the
opportunity to study oxytocin in relation to SRI-induced sexual
side effects. Our aims were to:
1. Identify possible correlates between baseline oxytocin plasma
levels and baseline sexual function;
2. Find out whether the degree of sexual side effects correlates
with plasma levels of oxytocin, with changes of oxytocin
induced by treatment, and/or with serum levels of paroxetine
and clomipramine;
3. Test whether incident changes of sexual functioning have any
relation to the anti-obsessive clinical response.METHODS
Patients
In a 12-week, multicenter, randomized, double-blinded,
parallel-group drug trial comparing ﬂexible doses of the SRIs
paroxetine (20e60 mg daily) and clomipramine (50e250 mg
daily) and placebo for the treatment of OCD, our center
included 43 patients with OCD.36 Of these, 36 patients
participated in a site-speciﬁc biochemical extension of the
trial,35,37 including plasma levels of oxytocin (at baseline and 1
and 4 weeks after treatment) and serum concentration of theSex Med 2016;4:e145ee155
Figure 1. Flowchart. CMI ¼ clomipramine treated; OCD ¼ obsessive-compulsive disorder; PBO ¼ placebo treated; PXT ¼ paroxetine
treated; SRI ¼ serotonin reuptake inhibitor; SSCL ¼ Sexual Symptom Checklist; w ¼ week.
Oxytocin and Sexual Effects in SRI-Treated OCD e147drugs (after 4 weeks). Information on sexual function ratings for
at least one time point was available for 35 of these 43 patients
and oxytocin levels were available in 36. Oxytocin levels and
sexual function were available in 31 patients (15 men and
16 women). Of these, 17 were single and 14 were cohabiters.
Mean age was 40.8 years (SD ¼ 11.1 years, minimum ¼ 18.1
years, maximum ¼ 57.2 years). Mean age at onset of OCD was
13.9 years (SD ¼ 6.7 years). Mean duration of OCD was 26.9
years (SD ¼ 13.0 years). Twenty-one patients (68%) were
SRI naive, and none had been taking antidepressant agents
during the preceding 3 months. Their mean Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS)38 score was 25.1
(SD ¼ 5.7) at baseline and their mean Montgomery-Åsberg
Depression Rating Scale (MADRS)39 score was 11.9 (SD ¼ 7.8).
Figure 1 shows a ﬂowchart of subject selection. Details on the
criteria for inclusion and exclusion of patients have been pub-
lished elsewhere.35e37Sex Med 2016;4:e145ee155MAIN OUTCOME MEASURES
Measurements of Sexual Function and Side Effects
and the Sexual Symptom Checklist
Using a semistructured interview, the Limited Symptom
Checklist, administered by the clinician, anticipated adverse ef-
fects were quantiﬁed. Eight of the 14 items on this checklist
concern sexual function, closely following the items reported in
an early study of clomipramine-induced anorgasmia.40 These
items are (i) interest in sex, (ii) sleepiness interfering with sexual
function, (iii) frequency of sex or masturbation, (iv) erection
(men) or lubrication (women), (v) sexual sensation, (vi) intensity
of orgasm, (vii) difﬁculty or increased time to reach orgasm, and
(viii) intensity of pain at orgasm. Each item was graded “none,”
“low,” “medium” or “high.” The clinician was instructed to
perform this interview at baseline and at each visit during the
12-week trial. For the present study, the sleepiness and pain
Table 1. Mean scores on each item from the SSCL in 32 patients with obsessive-compulsive disorder between men and women and score
changes after 6 weeks of double-blinded treatment between treatments*
SSCL items graded 0e3
Pretreatment ratings (n ¼ 32)
Score changes after 6 wk of treatment
(n ¼ 27)
Men
(n ¼ 18)
Women
(n ¼ 14) MW-U P value
SRIs
(n ¼ 21)
Placebo
(n ¼ 6) MW-U P value
1 Sexual interest 1.9 1.6 90.5 .18 0.05 0.17 50.0 .48
2 Sexual frequency 1.7 1.2 73.5 .045 0.05 0.00 58.5 .80
3 (men) Erection 1.9 .08 (n ¼ 12) 0.00 (n ¼ 3) 16.5 .84
3 (women) Lubrication 1.6 0.11 (n ¼ 9) 0.33 (n ¼ 3) 8.5 .37
4 Sexual sensation 1.8 1.6 113 .64 0.00 0.50 42.0 .24
5 Orgasm intensity 1.9 1.5 95.5 .25 0.38 0.33 36.0 .12
6 Orgasm difﬁculty or delay—R† 2.8 2.0 59.0 .01 1.81 0.00 18.5 .007
SSCL total score (0e18) 12.1 9.6 62.5 .014 2.29 1.17 14.0 .003
MW-U ¼ Mann-Whitney U-test; SRIs ¼ serotonin reuptake inhibitors; SSCL ¼ Sexual Symptom Checklist.
*Higher scores denote less sexual dysfunction. Mann-Whitney U-test was used for group comparisons. Means are presented because the small number of
alternative scores for each item made medians and quartiles uninformative. SDs varied from 0.4 to 1.0 for the separate items; also see Table 2.
†The scoring of this item is reversed to comply with the other items (ie, higher scores denote less orgasm difﬁculty).
e148 Humble and Bejerotitems (items ii and viii) were excluded, because of questionable
relevance and low endorsement rate, respectively. The six
remaining items, constituting the Sexual Symptom Checklist
(SSCL) in the present study, are strikingly similar to the Arizona
Sexual Experience Scale (ASEX),41 commonly used in psycho-
pharmacology studies. Each item of the SSCL was graded from
0 to 3 and included in our analyses as Likert-type items (Table 1
presents item content). The item “difﬁculty or increased time to
reach orgasm” was reversed, because higher points for all other
items denote improved or increased sexual function. Then, the
six items could be summed to a SSCL total score, approximating
general sexual functioning.Simulation of ASEX Scores
The Limited Symptom Checklist was an “ad hoc” scale for the
multicenter study that had not been validated, and to our
knowledge, the results at the multicenter level from this scale
were never published.36 Therefore, to support the use of the
SSCL, we mathematically transformed our SSCL scores to
simulate the differently scored but otherwise similar ASEX (ﬁve
items scored 1e6). For this purpose, grade 0 (very poor func-
tion) in the SSCL was replaced by grade 6, grade 3 (optimal
function) was replaced by grade 1, and the other grades corre-
spondingly in between (with the reversed item ﬁtted accord-
ingly). Of the ﬁve ASEX items, two (“penile erection or vaginal
lubrication” and “ability to reach orgasm”) are almost exactly
equivalent to two items in the SSCL; “satisfaction from orgasm”
in the ASEX corresponds well to “intensity of orgasm” in the
SSCL. Of the remaining SSCL items, “interest in sex” and
“frequency of sex” can reasonably substitute for “arousal” and
“drive,” respectively, on the ASEX, making the last SSCL item,
“sexual sensation,” superﬂuous. With transformation, our scores
could be directly compared with ASEX scores from two pub-
lished studies,26,42 in which patients with OCD were comparedwith other psychiatric subjects and healthy controls concerning
their sexual functions (Table 2).
In addition, the utility of the SSCL was probed by its ability to
detect differences between men and women, as reported by the
ASEX41 and changes induced by SRI treatment1,3 (Table 1).
To categorize the level of sexual side effects, we created two
indices from the SSCL: “markedly decreased sexual interest”
(items 1e4) and “markedly impaired orgasm” (items 5 and 6).
For each index, items were added, and a worsening from baseline
of at least two points was required for endorsement.
Measurements of OCD and Response to Treatment
Ratings of OCD symptom severity and depression were assessed
with the Y-BOCS38 and the MADRS, respectively.39 In addition,
possible adverse effects were elicited by open questioning.
Response to treatment was deﬁned as a score decrease of at
least 25% on the Y-BOCS and a rating of 1 or 2 (“very much
improved” or “much improved,” respectively) on the Patients’
Global Evaluation (a self-rating version of the Clinical Global
Impression improvement scale)43 after 12 weeks of treatment.
Measurements of Plasma Oxytocin and Serum
Antidepressant Concentrations
After an overnight fast, blood samples for analyses were taken
from 8:00 AM to 9:00 AM after a 10-minute rest in a calm room,
at baseline, and after 1 and 4 weeks of double-blinded treatment.
All samples were frozen and analyzed in the same assay. For
oxytocin, plasma was stored, samples were extracted before assay,
and the concentration of oxytocin was measured with a speciﬁc
radioimmunoassay; for details, see Humble et al.35
Regarding antidepressant concentrations, serum samples were
considered as reasonable steady-state trough values. Paroxetine
and clomipramine serum concentrations were analyzed afterSex Med 2016;4:e145ee155
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Oxytocin and Sexual Effects in SRI-Treated OCD e149extraction with high-performance liquid chromatography with
UV detection as previously described.44 When patients with
depression were treated with paroxetine 40 mg/day, their median
level was 125 nmol/L, (quartile 1 ¼ 105 nmol/L, quartile 3 ¼
400 nmol/L). To enable statistical calculations of the two drugs
together, Z scores were generated and used in combined analyses.Ethics
The study was approved by the research ethical committee of
the Karolinska Institutet (Stockholm, Sweden), and informed
consent was obtained from all participants.Statistics
Because items in the SSCL and oxytocin levels were non-
normally distributed, non-parametric tests (Mann-Whitney
U-test with two-by-one-sided exact P values and Spearman rank
order correlation) were applied. However, means are presented
for clarity in Table 1, and means and SDs are presented in
Table 2 to facilitate comparisons with other research. Otherwise,
medians and quartiles were used. Statistica 12 (StatSoft, Inc,
Tulsa, OK, USA) was used. Probabilities less than .05 were
considered signiﬁcant.RESULTS
Baseline Sexual Functions
Thirty-two patients (18men and 14women) responded reliably
to all six items from the SSCL at baseline (Table 1). For 27
patients, complete ratings from baseline and 6 weeks were avail-
able, and for 19 patients we had access to complete SSCL ratings
from all three time points and oxytocin concentrations at baseline
and week 4. Men reported higher scores than women on sexual
frequency, and women reportedmore difﬁculties reaching orgasm.
There were no differences at baseline between single and cohab-
iting subjects or among randomized treatment groups (paroxetine,
clomipramine, and placebo) for any of the SSCL items.Simulation of ASEX Scores
As presented in Table 2, our SSCL score transformations
produced sums that were somewhat lower than published reports
of genuine ASEX scores from other patients with OCD26,42
(P ¼ .02). However, except for orgasm ability, for which the
Swedish men reported substantially less dysfunction compared
with the men in the study by Kendurkar and Kaur26 (P <
.0001), no differences were found among women or men
regarding scores on all remaining items (including orgasm ability
in women).Oxytocin Plasma Levels and Sexual Functions at
Baseline
In 28 of the 32 patients, plasma oxytocin and SSCL ratings at
baseline before treatment were available. Median baseline levels
of oxytocin were 35.6 pg/mL (28.2e39.6 pg/mL) and 28.5
00.5
1
1.5
2
2.5
3
21keeW6keeW0keeW
Interest PLC Erect/Lubr PLC Org ease PLC
Interest SRI Erect/Lubr SRI Org ease SRI
Figure 2. Sexual functioning in paroxetine-, clomipramine-, and placebo-treated patients with obsessive-compulsive disorder for 12
weeks. Mean levels over time of three items from the Sexual Symptom Checklist (sexual interest, erection or lubrication, and difﬁculty to
reach orgasm) are shown. Only completers of all three time points were included (SRI group, n ¼ 17; placebo group, n ¼ 4). Signiﬁcant
differences between groups were found only for difﬁculty to reach orgasm at week 6 (t19 ¼ 3.5, P ¼ .002) and at week 12 (t19 ¼ 2.2,
P ¼ .043). Erect ¼ erection; Lubr ¼ lubrication; PLC ¼ placebo; SRI ¼ serotonin reuptake inhibitor.
e150 Humble and Bejerotpg/mL (22.6e37.1 pg/mL) in men and women, respectively
(Mann-Whitney U-test ¼ 71.5, P ¼ .24). Oxytocin at baseline
was not related to any of the SSCL items, MADRS scores, age, or
duration of OCD, but was related to baseline OCD severity
(Y-BOCS scores, n ¼ 28, Spearman rs ¼ 0.39, P ¼ .04).Treatment-Induced Changes of Sexual Functions
After 6 weeks of double-blinded treatment, the SRI-treated
patients reported delayed orgasm, whereas other individual
items in the SSCL did not differ among groups (Table 1).
The index “markedly decreased sexual interest” after 6 weeks
of treatment was endorsed by 6 of 19 SRI-treated patients (32%)
and by 0 of 5 placebo-treated patients (0%; n ¼ 24, missing
data ¼ 7, c21 ¼ 2.1, P ¼ .15). The index “markedly impaired
orgasm” at week 6 was endorsed by 16 of 22 SRI-treated patients
(73%) and by 1 of 5 placebo-treated patients (20%; n ¼ 27,
missing data ¼ 4, c21 ¼ 4.9, P ¼ .028). No differences were
found between paroxetine- and clomipramine-treated patients on
any item. For 21 patients, we had ratings from baseline, 6 weeks,
and 12 weeks. For these patients, the evolution over time of three
items from SSCL is shown in Figure 2. From all comparisons
among treatment groups, the only consistent effect of SRI
treatment was delayed orgasm. Three women who refrained from
responding to the SSCL at baseline because of low interest or no
sexual activity responded after 6 and 12 weeks, apparently
because their sexual activity had increased. All three were treated
with paroxetine.Sexual Side Effects and Treatment Response in
Relation to Plasma Oxytocin
Signiﬁcantly higher oxytocin levels at week 4 were associated
with “markedly impaired orgasm” at week 6 of SRI treatment
(P ¼ .005, Cohen d ¼ 1.06). In these patients, oxytocin plasmalevel increased by 17% from baseline to week 4, whereas those
without impaired orgasm function had a 2% decrease of their
oxytocin levels during the same period (not signiﬁcant; Table 3).
No association between “markedly decreased sexual interest”
and levels of SRIs or oxytocin was found, and there was no
association between serum levels of SRIs and “markedly impaired
orgasm.”
When oxytocin levels at week 4 were split by the median into
a high and a low group in the SRI-treated patients, 11 of 11
(100%) in the high group vs 5 of 10 (50%) in the low group
reported orgasmic delay (c21 ¼ 7.22, P ¼ .007). Using the same
median split to compare anti-obsessive treatment response, the
high oxytocin group was signiﬁcantly more likely to respond to
treatment than the low oxytocin group (c21 ¼ 4.31, P ¼ .038).Serum Levels of SRI
Serum concentrations of paroxetine (n ¼ 13, mean ¼ 116
nmol/L, SD ¼ 72 nmol/L) and clomipramine (n ¼ 5,
mean¼ 230 nmol/L, SD¼ 102 nmol/L) were available in all but
one patient treated with clomipramine. However, one paroxetine-
treated patient (a non-responder with markedly delayed orgasm
function) had no measurable concentration of paroxetine at week
4, suggesting he had taken a drug holiday. Therefore, he was
removed from the analysis presented in Table 3. The SRI con-
centrations did not differ according to adverse sexual effects,
decreased interest, or delayed orgasm (Table 3).Anti-Obsessive Response and Sexual Functions
Of the 16 SRI-treated patients reporting markedly impaired
orgasm at week 6, 12 (75%) were classiﬁed as responders on
OCD ratings after 12 weeks of SRI treatment. Three of the six
patients (50%) without impaired orgasm responded to SRI
treatment (not signiﬁcant). Of the ﬁve placebo-treated patientsSex Med 2016;4:e145ee155
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Oxytocin and Sexual Effects in SRI-Treated OCD e151with at least two SSCL ratings, the one responder reported no
orgasm impairment.
When subjects were divided according to sex, 12 men were
treated with an SRI. Ten reported impaired orgasm, 8 of these
were responders compared with none of the 2 without orgasm
impairment (c21 ¼ 4.8, P ¼ .028). Among the 10 SRI-treated
women, 6 reported impaired orgasm and 4 of these were
responders (67%). Of the four women without orgasm impair-
ment, three (75%) were responders (not signiﬁcant).DISCUSSION
In this study, we found a relation between higher oxytocin
levels after 4 weeks of SRI treatment and treatment-induced
delayed orgasm in patients with OCD. We also found that
delayed orgasm in men was related to an anti-obsessive treatment
response with SRIs. Furthermore, our results suggested that
oxytocin levels have greater impact on orgasmic function than
the concentration of the SRI drugs per se. In fact, clomipramine
serum levels were numerically lower in patients with delayed
orgasm than in those without.
Approximately 70% of patients treated with paroxetine for
depression have reported sexual dysfunction when carefully
investigated,45 in accordance with our ﬁndings in OCD. Inter-
estingly, three paroxetine-treated women in the present study
reported increased libido and sexual function, and this was not
linked to signiﬁcant changes of depression ratings. This could
represent a “forme fruste” of previously reported hypersexual
states during SRI treatment.46 As opposed to decreased libido,
delayed orgasm is not related to depression and could constitute
the most speciﬁc SRI-induced sexual effect. Indeed, one SRI
drug (dapoxetine) is speciﬁcally marketed for the treatment of
premature ejaculation.
The exact mechanisms by which SRIs cause delayed orgasm
are not known, although central serotonergic transmission is
certainly involved.2,7,45 The main endocrine candidates related to
orgasmic function are prolactin and oxytocin,47 but only pro-
lactin has been investigated previously in clinical samples. SRI
drugs increase prolactin,48 and in a study of consecutive men
consulting an andrology clinic for sexual dysfunction, prolactin
levels were indeed higher in men treated with SRIs,9 even if no
associations between prolactin and sexual effects were presented.
In line with this, it was hypothesized that sexual function could
be improved in patients treated by an SRI for depression by
adjunctive treatment with aripiprazole (predictably decreasing
prolactin levels). However, no correlation between orgasm
function and change in prolactin levels emerged48; accordingly,
increased prolactin is less likely to cause SRI-induced orgasmic
dysfunction. Oxytocin involvement in SRI-induced delayed
orgasm has not been explored in humans, but our ﬁndings
suggest an inﬂuence of the oxytocin system. However, they are at
variance with the hypothesis by de Jong et al21 suggesting that
SRI-induced orgasm delay is related to a decrease of oxytocin;
our results suggest the reverse. Consistent with our ﬁndings, a
e152 Humble and Bejerotdrug trial with an oxytocin antagonist for treating premature
ejaculation showed no clinically or statistically signiﬁcant effect
on the condition.49 Also supporting our ﬁnding are the sexual
effects of 3,4-methylenedioxy-methamphetamine (“Ecstasy”), an
indirect serotonin agonist and a powerful oxytocin releaser.50
Despite enhanced sexual desire, 80% of men and 40% of
women using the drug have reported delayed orgasm.51 A
hypothetical explanation of the discrepancy between animal
studies and the present study might be related to the temporal
patterns of oxytocin during orgasm. Plausibly, a rapid rise of
oxytocin could determine the orgasm mechanism.52 If so, then
an SRI-induced elevated baseline could decrease the amplitude of
this surge, thus impairing orgasmic liability. Most likely, these
processes are located within the hypothalamic neuronal network,
and our plasma measurements could represent only a reﬂection
of these processes.
In this study, we found a signiﬁcant relation between incident
orgasmic dysfunction and anti-obsessive response in SRI-treated
men but not in women. The fact that women had signiﬁcantly
lower points on orgasmic function at baseline might have pre-
cluded an identiﬁcation of any such association among women
with our sample size. Because both delayed orgasm and anti-
obsessive response35 seem related to increased plasma oxytocin,
the relation between sexual side effects and an anti-obsessive
response as reported by Ackerman et al31,32 might not merely
reﬂect compliance to drug treatment. Together, these results
support an involvement of oxytocin in OCD pathophysiology and
in the anti-obsessive and orgasm-delaying mechanisms of SRIs.
Patients with OCD respond slowly to SRI treatment
compared with patients with other SRI-responsive disorders,
such as major depression or premenstrual dysphoric disorder. A
period of 12 weeks is recommended for an anti-obsessive effect,
and higher doses are often required.30 If orgasm delay is an early
sign predicting treatment outcome (as suggested by our ﬁndings),
then termination after 4 weeks could spare the patient trouble-
some and ineffective treatment.Limitations
This study has several limitations that should be addressed,
and the most serious limitation is the small sample. For example,
we could not show that an increase in oxytocin levels from
baseline to week 4 was signiﬁcantly higher between those with
orgasm delay and those without. However, the difference be-
tween the two groups was substantial (þ17% vs 2% in
oxytocin levels) and could represent a type II error.
The SSCL was not validated, but at the time of our study, no
suitable scale had been published. However, results presented in
Tables 1 and 2 support a reasonable sensitivity to change and to
differences among groups. In psychopharmacology studies, the
ASEX is commonly used, and our simulation supports a similar
utility. Our lower scores for orgasm ability could be explained by
the reversed formulation of this item in the SSCL. Another likelyexplanation is that patients in the compared studies might have
used SSRIs, which likely affected this particular item. Such use
was carefully excluded at baseline in our study but was
acknowledged in a comparison study.42 Indeed, compared with
the other samples, the sexual function of our patients appears
more similar to healthy controls than to patients with major
depression. Nevertheless, the generalizability of our ﬁndings is
limited by the fact that only patients with OCD were studied.
Oxytocin in plasma has a short half-life and can change
rapidly, but we did not collect serial plasma samples. However,
our single samples were taken in a standardized way, and the
associations with sexual function and treatment response indicate
that plasma oxytocin levels do reﬂect some relevant aspect of
central oxytocin mechanisms.35
At the end of the trial, some measurements of sexual function
seemed to show subtle improvement. This could indicate that
the trial was of insufﬁcient duration to determine the persistence
of sexual side effects. Long-term studies are necessary to resolve
this issue.
When interpreting our ﬁndings, it should be considered that
our study population had OCD. Although sexual dysfunction is
consistently reported in SRI-treated patients, irrespective of
diagnosis, the relation between oxytocin and sexual dysfunction
could be speciﬁc to OCD.
This study presents data at least 20 years old. Because of a
binding agreement between the pharmaceutical company fund-
ing the study and the researchers, there was no legal possibility to
publish these data sooner. The company was aware of the
extensive sexual side effects of the drugs because the SSCL items
were included in the study protocol; however, they refrained
from publishing them. What they did publish and carefully
categorize were the spontaneous reports of adverse events that
subjects were asked for at each visit.36 Presumably, the patients
and the clinicians tended to avoid double reporting of sexual
adverse events. In consequence, in almost 300 participants
treated with SRIs, no sexual adverse events (but a number of
others) were communicated. Our cohort represents 11% of the
participants in the multicenter trial, a large proportion was drug
naive, and we had only one placebo responder. In the early
1990s, there was an unawareness of sexual adverse events from
SRIs,53,54 decreasing the likelihood that these were “nocebo”
effects. This has the effect of increasing the validity of this study’s
results.CONCLUSION
This pilot study lends some support to the notion that some
collateral effects of SRIs, particularly delayed orgasm, might be
exerted through changes within the oxytocinergic system and are
related to anti-obsessive mechanisms. Early signs of delayed
orgasm in SRI-treated patients with OCD could serve as a
clinical predictor for treatment response. Future studies shouldSex Med 2016;4:e145ee155
Oxytocin and Sexual Effects in SRI-Treated OCD e153explore the utility of this ﬁnding in other patient groups treated
with SRIs.
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